Medications After Adolescent Bariatric Surgery

• Status: Not yet recruiting
• Trial end date: 2022-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the feasibility to assess practicality of early weight loss medication usage in adolescent patients post-VSG with inadequate weight loss. Participants who enroll in the study will be prescribed off-label use of weight loss medications for a period of up to 1 year.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Janey Pratt
• Collaborator: Maternal and Child Health Research Institute
• Treatments: Phentermine; Topiramate

Criteria

Inclusion Criteria:

• Surgical patients in the LPCH/Stanford bariatric and weight management clinics

• Inadequate weight loss after vertical sleeve gastrectomy

Exclusion Criteria:

• Adequate weight loss after surgery;

• Unwilling to consent or adhere to safety monitoring plan;

• Any life-threatening or terminal diseases

• Currently pregnant, breastfeeding, or thinking of becoming pregnant

• Allergy or medical contraindication to phentermine or topiramate;

• History of drug or alcohol abuse;

• No known medication interactions;

• Significant renal or hepatic impairment;

• Participation in a study of an investigational medication 30 days prior to screening, while the patient is on study, and for 30 days after their last dose of study treatment